Gene expression profiling of lymphoid malignancies

Annual Review of Medicine

Volumn 53, Issue , 2002, Pages 303-318

  Staudt, Louis M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

BCL 6; Genomics; Leukemia; Lymphoma; Microarray

Indexed keywords

CELL DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 6;

ANTIBODY PRODUCTION; B CELL LYMPHOMA; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA; LYMPHOMA; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION;

DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA; LYMPHOMA; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-6; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 0036183437     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.53.082901.103941     Document Type: Review

References (59)

1. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
2. Molecular classification of cutaneous malignant melanoma by gene expression profiling
3. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
4. Molecular portraits of human breast tumours
5. Quantitative monitoring of gene expression patterns with a complementary DNA microarray
6. Genomic views of the immune system
7. Pharmacogenomics: Translating functional genomics into rational therapeutics
8. The Lymphochip: A specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes
9. The cancer genome anatomy project: Building an annotated gene index
10. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report
11. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma
12. A predictive model for aggressive non-Hodgkin's lymphoma
13. Current approaches to the management of non-Hodgkin's lymphoma
14. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
15. Cluster analysis and display of genome-wide expression patterns
16. Molecular definition of the germinal centre stage of B-cell differentiation
17. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas
18. Clonal evolution of a follicular lymphoma: Evidence for antigen selection
19. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells
20. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo
21. CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans
22. Human immunoglobulin (Ig)M+IgD+peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells
23. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
24. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia
25. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia
26. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors
27. Relation of gene expression phenotype to immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia
28. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features
29. Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells
30. Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies
31. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia
32. Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies
33. Leukemic cells from progressive B-CLL respond strongly to growth stimulation in vitro
34. Regulation of lymphocyte cell fate decisions and lymphomagenesis by BCL-6
35. Bcl-6 protein is expressed in germinal-center B cells
36. BCL-6 gene product, a 92- to 98-kD nuclear phosphoprotein, is highly expressed in germinal center B cells and their neoplastic counterparts
37. BCL-6 expression during B-cell activation
38. Control of inflammation, cytokine expression, and germinal center formation by BCL-6
39. Disruption of the Bc16 gene results in an impaired germinal center formation
40. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation
41. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: A novel function for the BTB/POZ domain as an autonomous repressing domain
42. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor
43. Transcriptional repression by the proto-oncogene BCL-6
44. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control
45. In situ studies of the germinal center reaction
46. Germinal centers
47. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells
48. Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6
49. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest
50. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
51. Cell-cycle-regulated DNA double-stranded breaks in somatic hypermutation of immunoglobulin genes
52. DNA double-strand breaks in immunoglobulin genes undergoing somatic hypermutation
53. Gene expression physiology and pathophysiology of the immune system
54. Signaling and circuitry of multiple MAPK pathways revealed by a matrix of global gene expression profiles
55. Probing lymphocyte biology by genomic-scale gene expression analysis
56. Gene regulation mediated by calcium signals in T lymphocytes
57. Genomic-scale gene expression profiling of normal and malignant immune cells
58. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses